Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho's General Account Budget for FY2009 Increased to ¥25,156.8 Bil.
January 12, 2009
- Medwatcher Japan Asks Korosho to Conduct Survey on Online Sales of Drugs
January 12, 2009
- FY2009 Budget Proposal Includes ¥24,592 Bil. for Social Security
January 12, 2009
- Consumer, Patient Groups Present Questions to Rakuten
January 12, 2009
- METI to Earmark ¥4.3 Bil. to Develop Regenerative Medicine Technology
January 12, 2009
- Ain to Jointly Open New Store in Sapporo with Seven & i
January 12, 2009
- REGULATORY NEWS IN BRIEF
January 12, 2009
- Take Risks to Develop Breakthrough Drugs: FPMAJ President Dr Takenaka
January 12, 2009
- Takeda Begins PIII Trial of ATL-962 for Obesity Licensed from Alizyme
January 12, 2009
- PMDA's Review System Needs Much More Enhancement for Med. Devices
January 5, 2009
- JPMA and LEEM Exchange Opinions
January 5, 2009
- EVEC Aims at Licensing of More Antibodies
January 5, 2009
- PMDA to Set Numerical Goals for OTC Drugs, Generics
January 5, 2009
- Yakult Licenses ThermoDox from Celsion
January 5, 2009
- REGULATORY NEWS IN BRIEF
January 5, 2009
- Diovan Ranked No. 1 on Both GP and HP Markets: Rep Track Survey
January 5, 2009
- GSK to Directly Compare Pazopanib with Sunitinib in RCC
January 5, 2009
- Combinations of Physical Detailing and e-Detailing Have Varying Effects, Depending on Drug Category
January 5, 2009
- Eldecalcitol Reduces Incidence of New Vertebral Fractures: Chugai, Taisho
January 5, 2009
- JMHA Considers Joint Purchases
January 5, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…